The year 2012 has been a great one for approvals for PharmaLogic. Four products on which we made substantial contributions were approved in the U.S. : iStent® Trabecular Micro-Bypass Stent, Jetrea® (ocriplasmin), Kyprolis® (carfilzomib), and Myrbetriq® (mirabegron).
- Paper published in American Journal of Ophthalmology
- Dr. Novack presents ophthalmology research at University of Wisconsin
- University of California Library and Elsevier Continue to Disagree
- NDA Partners Featured in Article on Growth of Pharma Disruptors
- Predatory journals – just say no!
- Sonoma Eye – Dr. Novack chair symposium on research and outcomes